Alvotech (ALVO) stock
Close on Nov 13, 2026Market cap $1.31BP/E 41.9Yield –
Alvotech grew revenue 19.7% to $586.32M over fiscal 2025. Operating income rose 12.3% to $78.21M, moving the operating margin from 14.2% to 13.3%. Free cash flow was -$114.67M. At the latest close the market valued the company at $1.31B, 41.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $1.31B
- P/E ratio
- 41.9
- Price to sales
- 2.23
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -8.77%
Fundamentals
- Revenue
- $586.32M
- EPS, diluted
- $0.10
- Free cash flow
- -$114.67M
Trading
- Previous close
- $4.67
- Open
- $4.58
- Day's range
- $4.13 – $4.63
- Volume
- 2,091,332
- Average volume (20 days)
- 999,226
- Beta (5 years)
- 0.43
- 52-week range
- $2.94 – $6.53
- RSI (14 days)
- 35.9
- Volatility (1 year)
- 71.5%
- Relative volume
- 2.06×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALVO | S&P 500 | Difference | ALVO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.1% | -3.0% | −19.1 pts | ||
| 3 months | +2.4% | -2.8% | +5.2 pts | ||
| Year to date | -18.3% | +11.5% | −29.8 pts | ||
| 1 year | -24.1% | +13.5% | −37.6 pts | ||
| 3 years | -53.5% | +77.7% | −131.2 pts | -22.6% | +21.1% |
| 5 years | -57.7% | +72.6% | −130.3 pts | -15.8% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025, USD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Alvotech filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Alvotech
Biological Products, (No Diagnostic Substances)
Alvotech is a vertically integrated biotechnology company dedicated exclusively to the development and manufacture of biosimilar medicines. The company identifies, researches, and produces biosimilars across therapeutic areas such as autoimmune disorders, oncology, eye conditions, respiratory illness, and bone diseases. Rather than selling directly to end consumers or healthcare providers, Alvotech out-licenses its commercial rights to leading global and regional pharmaceutical partners, who handle local distribution and sales in exchange for milestones and royalties.
Company profile, executives and historyAlvotech stock: common questions
What is Alvotech's stock price?
ALVO closed at $4.19 on Nov 13, 2026, down 10.28% on the day. Over the past 52 weeks it traded between $2.94 and $6.53.
What is Alvotech's market cap?
Alvotech was worth $1.31B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ALVO's P/E ratio?
ALVO trades at 41.9 times earnings, based on diluted earnings per share of $0.10 over fiscal 2025.
How much revenue does Alvotech make?
Alvotech reported revenue of $586.32M for fiscal 2025, up 19.7% from a year earlier.
Does Alvotech pay a dividend?
No. Alvotech has not paid a cash dividend over the last twelve months.
How has ALVO stock performed over the past year?
Including dividends, ALVO returned -24.1% over the past year, against +13.5% for the S&P 500.
Who are Alvotech's competitors?
Companies most similar to Alvotech by business, industry and size include IMCR, MGTX, TECH, BCRX, IOVA.
See a number that looks wrong?